Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Postgraduate Course ERS Copenhagen 2005 - Therapeutic options for interstitial lung diseases in 2005

R.P. Baughman, R.M. du Bois
Breathe 2006 2: 345-353; DOI: 10.1183/18106838.0204.345
R.P. Baughman
R.P. Baughman, University of Cincinnati Medical Center Holmes, Room 1001, Eden Avenue, Albert Sabin Way, 45267-0565 Cincinnati, OH, USA. Fax: 1 5135845110, E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bob.baughman@uc.edu
R.M. du Bois
R.M. du Bois, Royal Brompton Hospital, Sydney Street, SW3 6NP, London, UK. Fax: 44 2073518336 E-mail:
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: r.dubois@rbht.nhs.uk
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Educational aims

  • To discuss the role of corticosteroids in treating sarcoidosis.

  • To provide information about when to consider cytotoxic drugs for chronic sarcoidosis.

  • To outline how to monitor the use of cytotoxic drugs.

  • To better understand the differences in response when using anti-tumour necrosis factor agents in treating sarcoidosis

Summary The decision to treat a patient with sarcoidosis is dependent on many factors, the most important being whether the patient is symptomatic. Initial systemic therapy for symptomatic sarcoidosis usually includes corticosteroids. However, most symptomatic patients will require months to years of therapy. Therefore, alternatives to corticosteroids have been studied. This review will give a brief overview of the effect of corticosteroids and alternative treatments options available.

  • ©ERS 2006

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

PreviousNext
Back to top
Vol 2 Issue 4 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Postgraduate Course ERS Copenhagen 2005 - Therapeutic options for interstitial lung diseases in 2005
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Postgraduate Course ERS Copenhagen 2005 - Therapeutic options for interstitial lung diseases in 2005
R.P. Baughman, R.M. du Bois
Breathe Jun 2006, 2 (4) 345-353; DOI: 10.1183/18106838.0204.345

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Postgraduate Course ERS Copenhagen 2005 - Therapeutic options for interstitial lung diseases in 2005
R.P. Baughman, R.M. du Bois
Breathe Jun 2006, 2 (4) 345-353; DOI: 10.1183/18106838.0204.345
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Idiopathic pulmonary fibrosis and lung cancer
  • Diagnosis and management of PH related to chronic respiratory disease
  • Pulmonary renal syndrome: a clinical review
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society